Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of HPV Vaccine in TGW and MSM
NCT06588257Phase 4Completed
- Sponsor
- Fundación Huésped
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (4 arms), sponsored by Fundación Huésped. Primary endpoint: Proportion of people receiving the first dose and 3 doses of HPV vaccine at 12 months. Started Oct 2024; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06588257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588257.